{
    "paper_id": "0e7b6f9d905afba19bfda19cd0f0fa7158db2942",
    "metadata": {
        "title": "Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients",
        "authors": [
            {
                "first": "An",
                "middle": [
                    "S"
                ],
                "last": "De Vriese",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "AZ Sint-Jan Brugge-Oostende AV",
                    "location": {
                        "settlement": "Brugge",
                        "country": "Belgium"
                    }
                },
                "email": "an.devriese@azsintjan.be"
            },
            {
                "first": "Jens",
                "middle": [
                    "Van"
                ],
                "last": "Praet",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "AZ Sint-Jan Brugge-Oostende AV",
                    "location": {
                        "settlement": "Brugge",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "Marijke",
                "middle": [],
                "last": "Reynders",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Ghent University",
                    "location": {
                        "settlement": "Ghent",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "Liesbeth",
                "middle": [],
                "last": "Viaene",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "AZ Groeninge",
                    "location": {
                        "settlement": "Kortrijk",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "Rogier",
                "middle": [],
                "last": "Caluw\u00e9",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "OLV Hospital",
                    "location": {
                        "settlement": "Aalst",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "Melanie",
                "middle": [],
                "last": "Schoutteten",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Ziekenhuis Oost-Limburg",
                    "location": {
                        "settlement": "Genk",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "Dirk",
                "middle": [],
                "last": "De Bacquer",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Ghent University",
                    "location": {
                        "settlement": "Ghent",
                        "country": "Belgium"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the large majority of haemodialysis (HD) patients rapidly seroconvert [1] [2] [3] , with robust and durable serological responses up to 10 months [4] . These observations appear non-sequitur in view of the well-known immune dysfunction of HD patients, resulting in slower viral clearance and higher case fatality rates of SARS-CoV-2 infection, as well as impaired responses to SARS-CoV-2 vaccination [5] . A potential explanation may be that dialysis patients develop more severe disease with prolonged viral shedding and higher levels of pro-inflammatory cytokines, resulting in more intense immune stimulation. In a study of 2215 HD patients, older and diabetic patients had slightly higher antibody levels, but data on disease severity were not available [6] .",
            "cite_spans": [
                {
                    "start": 152,
                    "end": 155,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 156,
                    "end": 159,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 160,
                    "end": 163,
                    "text": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 228,
                    "end": 231,
                    "text": "[4]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 482,
                    "end": 485,
                    "text": "[5]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 840,
                    "end": 843,
                    "text": "[6]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "In the general population, robust T-cell responses have been observed in asymptomatic patients even in the absence of detectable antibodies, suggesting that T-cell immunity develops independently of disease severity [7] . A cohort of 14 HD patients, sampled a mean of 40 days after coronavirus disease 2019 diagnosis, displayed T-cell responses of similar intensity to those of patients with normal renal function [8] . Currently there are no data on the durability and correlation with disease severity of T-cell immunity in HD patients.",
            "cite_spans": [
                {
                    "start": 216,
                    "end": 219,
                    "text": "[7]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 414,
                    "end": 417,
                    "text": "[8]",
                    "ref_id": "BIBREF8"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Of the 569 patients on HD in March 2021, 41 had a history of polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection, of which 24 had asymptomatic or mild disease and 17 had severe disease requiring hospitalization (Supplementary data, Serological responses persisted up to >1 year, with a faster decay of anti-nucleocapsid protein (anti-N) immunoglobulin G (IgG) than anti-spike protein (anti-S) IgG ( Figure 1A and B) . Patients with severe disease had higher antibody levels ( Table 1 ), but the decay trajectory was similar. Interferon-c production by peripheral blood CD4 \u00fe and CD8 \u00fe lymphocytes was unaffected by disease severity (Table 1 ) and could be detected up to >1 year after infection but did not display a clear pattern of evolution over time ( Figure 1C ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 410,
                    "end": 426,
                    "text": "Figure 1A and B)",
                    "ref_id": null
                },
                {
                    "start": 487,
                    "end": 494,
                    "text": "Table 1",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 643,
                    "end": 651,
                    "text": "(Table 1",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 767,
                    "end": 776,
                    "text": "Figure 1C",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "In conclusion, the humoral response to SARS-CoV-2 infection in HD patients is a marker of disease severity. Prolonged viral antigen exposure and production of inflammatory cytokines Letter to the Editor Clinical Kidney Journal due to a more severe disease course may explain the intense and long-lasting antibody production in HD patients. Conversely, the cellular immune response is unaffected by disease severity and appears to be governed by as yet undetermined factors.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "This research was supported by a grant of Amgen (DONAT ION-331036). The funding source had no role in the design, conduct, or analysis of the study or the decision to submit the manuscript for publication. According to linear models for log10-transformed outcomes. GMT, geometric mean titre; GMC, geometric mean concentration.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "FUNDING"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "IgG antibodyresponse to SARS-CoV-2 infection and viral RNA persistence in patients on maintenance hemodialysis",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "De Vriese",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Reynders",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Am J Kidney Dis",
            "volume": "76",
            "issn": "",
            "pages": "440--441",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Kinetics of anti-SARS-CoV-2 IgG antibodies in hemodialysis patients six months after infection",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Sakhi",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Dahmane",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Attias",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "J Am Soc Nephrol",
            "volume": "32",
            "issn": "",
            "pages": "1033--1036",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "The cut-off for positivity (dashed line) was 50 AU/mL and the conversion factor to the World Health Organization binding antibody units (BAU/mL) is BAU/mL \u00bc 0.142 \u00c2 AU/mL. Anti-N IgG was measured by a CMIA on the same ARCHITECT i analyser (SARS-CoV-2 IgG assay, Abbott). A signal:cut-off ratio !1.4 (dashed line) was interpreted as reactive",
            "authors": [],
            "year": null,
            "venue": "The QuantiFERON SARS-CoV-2 test",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Clarke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Prendecki",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Dhutia",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Kidney Int",
            "volume": "99",
            "issn": "",
            "pages": "1470--1477",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "IgG SARS-CoV-2 antibodies persist at least for 10 months in patients on hemodialysis",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Dudreuilh",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Roper",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Breen",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Kidney Int Rep",
            "volume": "6",
            "issn": "",
            "pages": "1961--1964",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "A"
                    ],
                    "last": "Ikizler",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "T"
                    ],
                    "last": "Coates",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "H"
                    ],
                    "last": "Rovin",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Kidney Int",
            "volume": "99",
            "issn": "",
            "pages": "1275--1279",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Serial SARS-CoV-2 receptor-binding domain antibody responses in patients receiving dialysis",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Anand",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Montez-Rath",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Ann Intern Med",
            "volume": "174",
            "issn": "",
            "pages": "1073--1080",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Sekine",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Perez-Potti",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Rivera-Ballesteros",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "183",
            "issn": "",
            "pages": "158--168",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Anft",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Blazquez-Navarro",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Paniskaki",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Kidney Int",
            "volume": "99",
            "issn": "",
            "pages": "1489--1490",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Received: 26.7.2021; Editorial decision: 10.8.2021 V C The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com doi: 10.1093/ckj/sfab147",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": ". Patients were stratified by days between the PCR test and blood sampling into Period 1 [mean 348 days (range 327-378)] and Period 2 [mean 125 days (range 48-200)].",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Humoral and cellular response to SARS-CoV-2 infection stratified by disease severity and interval between infection and sampling",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "None declared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CONFLICT OF INTEREST STATEMENT"
        }
    ]
}